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Abstract: Venoms can deleteriously affect any physiological system reachable by the bloodstream,
including directly interfering with the coagulation cascade. Such coagulopathic toxins may be
anticoagulants or procoagulants. Snake venoms are unique in their use of procoagulant toxins for
predatory purposes. The boomslang (Dispholidus typus) and the twig snakes (Thelotornis species) are
iconic African snakes belonging to the family Colubridae. Both species produce strikingly similar
lethal procoagulant pathologies. Despite these similarities, antivenom is only produced for treating
bites by D. typus, and the mechanisms of action of both venoms have been understudied. In this
study, we investigated the venom of D. typus and T. mossambicanus utilising a range of proteomic
and bioactivity approaches, including determining the procoagulant properties of both venoms in
relation to the human coagulation pathways. In doing so, we developed a novel procoagulant assay,
utilising a Stago STA-R Max analyser, to accurately detect real time clotting in plasma at varying
concentrations of venom. This approach was used to assess the clotting capabilities of the two venoms
both with and without calcium and phospholipid co-factors. We found that T. mossambicanus produced
a significantly stronger coagulation response compared to D. typus. Functional enzyme assays showed
that T. mossambicanus also exhibited a higher metalloprotease and phospholipase activity but had
a much lower serine protease activity relative to D. typus venom. The neutralising capability of the
available boomslang antivenom was also investigated on both species, with it being 11.3 times more
effective upon D. typus venom than T. mossambicanus. In addition to being a faster clotting venom,
T. mossambicanus was revealed to be a much more complex venom composition than D. typus. This is
consistent with patterns seen for other snakes with venom complexity linked to dietary complexity.
Consistent with the external morphological differences in head shape between the two species, CT
and MRI analyses revealed significant internal structural differences in skull architecture and venom
gland anatomy. This study increases our understanding of not only the biodiscovery potential of
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these medically important species but also increases our knowledge of the pathological relationship
between venom and the human coagulation cascade.
Keywords: procoagulant; boomslang; Dispholidus typus; Thelotornis mossambicanus; colubridae;
enzyme activity; biodiscovery; evolution
1. Introduction
Venoms are used for competitor deterrence, defence, and prey capture. These chemical cocktails
use myriad protein types as starting substrates for the evolution of their toxic arsenals. Many of these
protein families have been convergently recruited into the secretions of various venomous animal
classes [1]. Novel expression of a normal body protein in the venom gland is followed by fixation and
diversification of the proteins, with duplication and diversification leading to neofunctionalisation.
In reptiles, such compounds have been recruited for use at different times in the diverse history of
venom in this lineage with relative expression levels rising and falling for a particular toxin type along
the evolutionary continuum [2]. As venoms evolve through the birth-and-death model of protein
evolution [3], there are many instances of toxins also being lost from within a lineage [4].
Rather than prey death, prey immobilization is the driving selection pressure upon the venom, as
there is no functional difference between a prey item that is physically unable to flee or defend itself
and one that is dead [5,6]. Prey capture involving chemicals will produce a different form of injury than
one involving mechanical subjugation techniques such as claws or cutting teeth. Interactions among
toxins are selected for a combined function, which facilitates prey subjugation in a time dependent
manner. Evolutionary pressures from other variables such as post-envenomation prey detectability and
prey escape potential also shape venoms. The evolutionary pressures acting upon predatory venoms
select specific actions that facilitate prey capture via target sites reachable by the blood. Actions upon
nerve action potentials and the blood clotting cascade are two particularly important areas. Venoms
that act on the nerves are typically used by species that include reptiles as major prey items in their diet.
The specific function selected for the case of elapid snakes, which feed on sleeping lizards, is caused by
alpha-neurotoxins, which antagonistically bind to the post-synaptic nicotinic acetylcholine receptor
to produce flaccid paralysis [7]. Conversely, the long-glanded blue coral snake (Calliophis bivirgatus)
and mambas (Dendroaspis species), which feed on active prey items with a high escape potential,
have presynaptic-acting venoms that produce excitatory neurotoxicity, resulting in uncontrollable,
uncoordinated spastic paralysis [6]. In the case of C. bivirgatus, there is an additional selection pressure
for rapid acting venom due to specialisation upon other venomous snakes, which in turn have a high
chance of prey retaliation.
Toxins that target the blood coagulation cascade do so in one of two mutually exclusive functional
mechanisms; overall net anticoagulation or procoagulation. Anticoagulant venoms, such as those
found in most pit-vipers, participate in the formation of haemorrhagic shock through a combined
chemical assault, which may include the use of procoagulant pathways as part of the net anticoagulant
function. Targets ranging from the cleavage of fibrinogen (whether outright destruction or the use
of procoagulant pathways to produce weak, unnatural clots that are readily broken down by the
abundant plasmin produced by synergistic toxins, which activate plasminogen) through to platelets
(aggregation inhibition or unnatural clumping effects, which disrupt the normal role platelets serve in
clotting), with these toxic effects accompanied by other toxins that increase the permeability of the
vascular bed [1,2,8–12]. These venoms are often employed by ambush feeding vipers, which specialise
upon warm-blooded prey items, and are able to be efficiently tracked post-bite using chemoreception
and heat detection sensory arrays [13,14]. In contrast, strong clot forming procoagulant venoms are
selected for lineages that feed upon prey with fast moving blood circulation rates. Such prey lineages
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are vulnerable to toxins that produce blood clots that rapidly subjugate through stroke induction, such
as taipans (Oxyuranus species) feeding upon rodents [15].
The African boomslang (Dispholidus typus) and the twig snakes (Thelotornis species) are closely
related iconic African snakes belonging to the family Colubridae, and both inhabit arboreal, predatory
niches that include prey items with a high potential for escape [16,17]. The limited work that has been
undertaken upon them has revealed that both have clot-forming, procoagulant venoms [17–22]. While
the venoms appear to be functionally similar in their potent action upon blood chemistry, the relative
complexity of the venoms is unknown. While Dispholidus has been shown to have a venom dominated
by P-III snake venom metalloprotease (SVMP) [22–24], other toxin types are present in the venom
in lower amounts [3,23]. In vipers, certain procoagulant P-III SVMPs have been shown to activate
prothrombin [25–28] or Factor X [27–29]. Strong clot forming procoagulant function has convergently
evolved in the venom of D. typus and similar activities are suggested for T. capensis [30]. The venom
composition for any Thelotornis species is unknown so the toxin type responsible for procoagulation
can only be inferred as likely being a P-III SVMP like its related genera Dispholidus. From a functional
perspective, these two related but very divergent snakes share a coagulotoxic action with their last
common ancestor [3,23]. These snakes have evolved procoagulant venoms convergently in relation to
vipers in the Daboia genus [31,32] or elapids in the Oxyuranus or Pseudonaja genera [33,34]. Daboia use
serine proteases to activate factor X, while Oxyuranus and Pseudonaja use a mutated factor Xa:factor Va
complex to escape hemostatic control [35].
Dispholidus is genetically close to the genus Thrasops. Dispholidus and Thrasops are in turn sister to
Thelotornis. The two genera studied here differ in their occupied niches and morphology. Dispholidus
is a monotypic genus consisting of the boomslang (D. typus), which is an active foraging snake
with very large eyes with circular pupils and acute vision, a large round head, and variable colour,
ranging from uniform brown to green with darkened scale edges [17,20]. The large head is quite
similar to the tree cobras (e.g., Naja goldii), including enlarged eyes. In contrast, Thelotornis is a genus
of ambush feeding, highly cryptically and intricately patterned snakes with large eyes, horizontal
pupils, and near binocular vision [17,20,36]. Their elongate heads are convergently similar to other
Colubridae, particularly the Ahaetulla genus from Asia and the Oxybelis genus of the southern U.S. and
Central America.
Birds account for the majority of Dispholidus prey items as it hunts in the canopy. The fast-moving,
endothermic blood circulatory system of avians is similar to mammals in being vulnerable to rapid
prey subjugation by stroke formation, thus neutralising the high escape potential posed by prey items
with flight ability. While lizards such as chameleons form a percentage of the Dispholidus diet [16,17],
they are non-dangerous and slow moving and are also taken during their diurnal activity period
when blood circulation is at its maximum. Thelotornis may have a more complex diet than D. typus
as it occupies a niche located near or on the forest floor and snakes of this genus are perhaps also
more likely to be sensitive to prey escape potentials due to their slower movements relative to the fast
moving Dispholidus [16,17,36].
Neither genus of snakes was thought to be of significant medical consequence until each killed an
eminent herpetologist (Robert Mertens and Karl Patterson Schmidt, respectively) [24]. However, the
ability for D. typus to cause serious harm to humans, and even death, had previously been reported
by F.W. Fitzsimons as early as 1909 [17,20,21,37–40]. Strikingly, T. capensis has been shown to produce
nearly identical human clinical symptoms as reported for D. typus, with death the result of internal
bleeding such as cerebral haemorrhage [19,30,41]. However, the existing antivenom manufactured to
treat bites caused by D. typus is said to be ineffective in cases of T. capensis envenomation [17,21,30].
While prey injected with significant concentrations of procoagulant venoms items succumb to
stroke [42], human deaths from these venoms are due to internal haemorrhage due to the dilution of the
procoagulant venom into a volume of blood much larger than the concentrated effects in prey animals,
resulting in defibrinogenation due to venom induced consumptive coagulopathy [2,15,28,41,43].
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Despite a monovalent antivenom existing and routinely administered to bite victims [17,22],
limited research has been conducted on the function of D. typus venom, with the literature being
dominated by bite case reports or proteomics in the absence of bioactivity testing. Even less is known
about Thelotornis venoms, with limited previous publications having mainly dealt only with T. capensis,
while the rest of the genus is unknown in its venom composition. We aimed to investigate the key
similarities and differences between the two genera utilising a range of proteomic and bioactivity
approaches to reconstruct their functional evolution in response to prey preference and ecological niche
occupied. It is hypothesised that T. mossambicanus has a greater diversity of venom toxin components,
reflective of its diverse diet and their associated heighted potential for prey escape, than the more
specialised feeder D. typus.
2. Results
2.1. Skull and Venom Gland Anatomical Comparisons
Both species displayed enlarged rear-fangs, consistent with their demonstrated efficient venom
delivery in predation and also defensive bites. Reflective of their difference in head shape, the
T. mossambicanus venom gland was more elongate than that of D. typus due to contributions by both
hard and soft tissue (Figure 1).
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dominated by P-III SVMP (Figures 2 and 3, Supplementary Data), T. mossambicanus also contained 
phospholipase A2 (PLA2 Type IIE) in high amounts. The presence of PLA2 Type IIE is a significant 
discovery as it is the third type of PLA2 to be characterised in snake venoms [44]. The molecular 
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typus [24]. 
Figure 1. Contrast tomography (left column) and magnetic resonance imaging (right column)
comparison of D. typus (top row) and T. mossambicanus (bottom row) venom delivery systems.
2.2. Proteomics
Shotgun mass spectrometry analysis recovered the same toxin types from each venom; CRiSP,
PLA2 Type IIE, 3FTx, and SVMP. However, 1D and 2D gels showed significantly different relative
abundances and complexity levels. While both 1D and 2D gels indicate that both species are dominated
by P-III SVMP (Figures 2 and 3, Supplementary Data), T. mossambicanus also contained phospholipase
A2 (PLA2 Type IIE) in high amounts. The presence of PLA2 Type IIE is a significant discovery as it is
the third type of PLA2 to be characterised in snake venoms [44]. The molecular weights of identified
P-III SVMP correspond to previous transcriptome and proteome data for D. typus [24].
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Figure 2. 1D SDS PAGE with identified groups of proteins. D.t = Dispholidus typus, T.m = Thelotornis
mossambicanus. Reduced conditions on the left, Non-reduced conditions on the right. Molecular weight
marker indicated by centered numbers (kDa). Annotations (right) refer to bands identified (white
numbers) within the reduced column.
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2.3. Enzymatic Assays
Fluorescent Determination of Matrix Metalloprotease and Kallikrein Activity
Despite T. mossambicanus having a more complex venom profile than D. typus, and thus lower
relative amounts of P-III SVMP (Supplementary Data), it actually displayed a higher rate of cleavage
of a matrix metalloprotease specific substrate (Figure 4). A two-way (RM) ANOVA (α = 0.05) indicates
that there is a significant difference in Column Factor (species and concentration), accounting for 78.6%
of the total variance (after adjusting for matching); F(3, 8) = 45.2, p < 0.001. Tukey’s post-hoc test
indicated that there is a significant difference in activity between D. typus and T. mossambicanus at a
concentration of 0.5 µg/100 µL (p ≤ 0.04). The levels of T. mossambicanus were of a high level, similar
to that of the viperid snake Gloydius saxitilis included for comparison.
Toxins 2016, 8, 171 6 of 20 
 
Fluorescent Determination of Matrix Metalloprotease and Kallikrein Activity 
Despite T. mossambicanus having a more complex venom profile than D. typus, and thus lower 
relativ  am unts of P-III SVMP (S pplem ntary Data), it ac ually displayed a higher rate of cleavage 
of a matrix metalloprotease specific substrate (Figure 4). A two-way (RM) ANOVA (α = 0.05) indicates 
that there is a significant difference in Column Factor (species and concentration), accounting for 
78.6% of the total variance (after adjusting for matching); F(3, 8) = 45.2, p < 0.001. Tukey’s post-hoc 
test indicated that there is a significant difference in activity between D. typus and T. mossambicanus 
at a concentration of 0.5 µg/100 µL (p ≤ 0.04). The levels of T. mossambicanus were of a high level, 
similar to that of the viperid snake Gloyd us saxitilis included for comparison. 
 
Figure 4. Snake Venom Metalloprotease Activity of venom (10 ng/µL and 50 ng/µL) was measured 
based on its ability to cleave a fluorogenic peptide substrate (Mca-PLGL-Dpa-AR-NH2 Fluorogenic 
MMP Substrate, Cat#ES001). Column graph of Matrix Metalloprotease activity assay of D. typus and 
T. mossambicanus obtained from normalisation of slope values. X axis: species name and concentration; 
Y axis: absorbance percentage. Analysis of triplicates was conducted on GraphPad PRISM 7.0 and 
error bars indicate standard deviation. 
Contrastingly, D. typus venom demonstrated a much higher kallikrein activity compared to that 
of T. mossambicanus. D. typus had an active concentration of 0.1 µg/100 µL and 0.5 µg/100 µL, 
compared to T. mossambicanus, which was only slightly active at 0.5 µg/100 µL (Figure 5). A two-way 
(RM) ANOVA (α = 0.05) indicates that there is a significant difference within the test, with Column 
Factor (species and concentration) accounting for 80.1% of the total variance (after adjusting for 
matching); F(3, 7) = 136.6, p ≤ 0.001. Tukey’s post-hoc test indicated that there is a highly significant 
difference in activity between D. typus and T. mossambicanus at both concentrations (p ≤ 0.001). This 
is indicated by the increased presence of kallikrein-like serine proteases in D. typus’ venom profile 
(Figure 2). However, even the proportionally higher D. typus activity levels were insignificant in 
relation to the representative viperid Trimeresurus vogeli included for comparison, thus indicating that 
this function is a trivial aspect of the venom, consistent with the non-detection in our proteomics and 
low-levels in the published D. typus venom gland transcriptome [24]. 
Figure 4. Snake Venom Metalloprotease Activity of veno (10 ng/µL and 50 ng/µL) was measured
based on its ability to cleave a fluorogenic peptide substrate (Mca-PLGL-Dpa-AR-NH2 Fluorogenic
MMP Substrate, Cat#ES001). Column graph of Matrix Metalloprotease activity assay of D. typus and
T. mossambicanus obtained from normalisation of slope values. X axis: species name and concentration;
Y axis: absorbance percentage. Analysis of triplicates was conducted on GraphPad PRISM 7.0 and
error bars indicate standard deviation.
Contrastingly, D. typus venom demonstrated a much higher kallikrein activity compared to that of
T. mossambicanus. D. typus had an active concentration of 0.1 µg/100 µL and 0.5 µg/100 µL, compared
to T. mossambicanus, whi h was only slightly active at 0.5 µg/100 µL (Figure 5). A two-way (RM)
ANOVA (α = 0.05) indicates that there is a significant difference within the test, with Column Factor
(species and concentration) accounting for 80.1% of the total variance (after adjusting for matching);
F(3, 7) = 136.6, p ≤ 0.001. Tukey’s post-hoc test indicated that there is a highly significant difference in
activity between D. typus and T. mossambicanus at both concentrations (p ≤ 0.001). This is indicated
by the increased presence of kallikrein-like serine proteases in D. typus’ venom profile (Figure 2).
However, even the proportionally high r D. typus activity levels were insignificant in relation to the
representative viperid Trimeresurus vogeli included for comparison, thus indicating that this function is
a trivial aspect of the venom, consistent with the non-detection in our proteomics and low-levels in the
published D. typus venom gland transcriptome [24].
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to cleave a fluorogenic peptide substrate (Boc-VPR-AMC Fluorogenic Peptide Substrate, Cat#ES011).
Column graph of Kallikerin activity assay of D. typus and T. mossambicanus obtained from normalisation
of slope values. There is a highly significant difference in activity between D. typus and T. mossambicanus
at both concentrations (p ≤ 0.001). X axis: species name and concentration; Y axis: absorbance as
a percentage. Analysis of triplicates was conducted on GraphPad PRISM 7.0 and error bars indicate
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2.4. Fluorescent Determination of sPLA2 ctivity
We tested for continuous secretory phospholipase A2 (sPLA2) enzymatic activity over 100
measurement cycles using and following the EnzChek® Phospholipase A2 Assay Kit (Cat#E10217).
T. mossambicanus showed increased levels of sPLA2 activity compared to D. typus at a concentration
of 50 ng/µL (Figure 6). This increase in activity by T. mossambicanus is also mimicked in the venom
profiling of both venoms via 1D SDS PAGE (Figure 2). A two-way RM ANOVA (α = 0.05) indicates
that there is a significant difference within the assay, with Column Factor (species and concentration)
accounting for 63.41% of total variance (after adjusting for matching); F(2, 6) = 78.75, p ≤ 0.001.
Tukey’s post-hoc test indicated there is a highly significant difference in activity between D. typus
from the positive control and between D. typus and T. mossambicanus (p ≤ 0.001). Tukey’s post-hoc
test also indicates a significant difference of T. mossambicanus from the positive control (p ≤ 0.01). The
T. mossambicanus levels were similar to that of the representative viperid snake Azemiops feae included
for comparison.
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2.5. Procoagulation Analysis
While both venoms were potently procoagulant, we find that the venom of T. mossambicanus
coagulates plasma much faster that that of D. typus (Figures 7 and 8). At a 20 µg/mL concentration,
T. mossambicanus venom clots the plasma on average in 7.5 s (SD 0.15 s), compared to D. typus, which
clots the plasma on average in 11.2 s (SD 0.06 s) (Table 1). The T. mossambicanus venom is amongst
the most potently coagulotoxic of any we have tested, being on par with Oxyuranus and Pseudonaja
venoms tested under id ntical conditions (unpublished results). At a 0.05 µg/mL concentration,
T. mossambicanus venom clots the plasma o average in 80.4 s (SD 0.52 s), compared to D. typus, which
clots the plasma on average in 146.6 s (SD 5.23 s) (Table 1). Figure 6 demonstrates th relative potency
of T. mossambicanus venom against human plasma, compared to D. typus, in the reduced variation in
clotting times between dilutions. The distance between the first vertical line and the second vertical
line is longer in T. mossambicanus than in D. typus, illustrating that there is a longer rise in clotting times,
depicting that T. mossambicanus venom holds its potency between dilutions more so than D. typus
(Figure 7, Table 2). This is also demonstrated by the point where the curve crosses the x axis, which
is higher in D. typus than in T. mossambicanus (R0 ϕ2 = 37.83 and 23.17 s respectively) (Table 2). The
additional investig tion with and without cofactors CaCl2 and phospholipid had no impact on the
clotting times of either species, with clotting times remaining the same at all dilutions (data not shown).
This is indicative of both venoms being calcium and phospholipid independent in exerting their
procoagulant coagulotoxic actions.
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Table 1. Average clotting times with standard deviations (SD) (in seconds) of D. typus and T.
mossambicanus at varying dilutions with and without the addition of boomslang antivenom.
Concentration
Without Antivenom With Antivenom
D. typus T. mossambicanus D. typus T. mossambicanus
Mean SD Mean SD Mean SD Mean SD
20 µg/mL 11.27 0.06 7.57 0.15 20.73 1.07 9.6 0.17
10 µg/mL 15.95 1.88 9.55 0.17 155 5.2 16 0.17
6.66 µg/mL 19.34 0.21 11.20 0.34 214.56 21.28 21.16 0.23
5 µg/mL 21.22 0.22 12.43 0.08 255 10.56 35.13 1.32
3.33 µg/mL 24.72 0.22 14.95 0.65 343.2 8.97 43.33 1.86
2.5 µg/mL 27.63 0.14 16.45 0.18 432.3 35.32 53.43 0.11
2 µg/mL 30.91 0.47 18.27 0.13 444.93 23.43 58.46 1.29
1.33 µg/mL 36.32 1.61 20.50 0.58 525.86 51.19 75.43 2.15
1 µg/mL 39.60 0.54 24.30 0.74 594.86 61.15 83.33 3.86
0.66 µg/mL 43.91 0.56 27.44 1.03 735.3 6.94 100.8 1.97
0.4 µg/mL 53.77 6.21 31.67 0.19 790.36 9.41 128.4 0.52
0.25 µg/mL 61.95 7.95 35.91 0.64 966.76 35.88 163.23 2.6
0.125 µg/mL 83.31 6.51 54.89 0.14 999 0 226.33 2.6
0.05 µg/mL 146.65 5.23 80.44 0.52 999 0 381.23 4.71
Table 2. Asymptotic regression model coefficient estimates for D. typus and T. mossambicanus normal
plasma clotting times. In this example, ϕ1 is the asymptote as x (concentration) approaches ∞, ϕ2 is the
response at x = 0, and t0.5 is the half-life. Parameter ϕ3 is the logarithm of the rate constant which is
used to enforce positivity so that an asymptote is reached in the model. The corresponding half-life is
written t0.5 = log2/exp(ϕ3). Analysis and output performed in R Studio (refer to methodology 4.4.3
Coagulation Statistical analysis).
Species
Coefficient Estimates
Aymϕ1 R0ϕ2 lrcϕ3
D. typus 9.095161 (s) 37.83835 (s) −0.6711807
T. mossambicanus 2.068652 (s) 23.17609 (s) −0.8289048
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Figure 7. Asymptotic plots of D. typus and T. mossambicanus procoagulation clotting against human
plasma. Asymptotic time depicted by horizontal line, D. typus asymptote 9.09 (s), T. mossambicanus
asymptote 2.06 (s). X axis: log concentration (µg/mL). Y axis: Time in seconds. Analysis and plots
created in R Studio.
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With the addition of diluted boomslang monovalent antivenom to the dilution series, it is evident
that the antivenom neutralises D. typus remarkably well, in contrast to having little neutralising
effect on T. mossambicanus (Figure 8). At 20 µg/mL venom concentration with the antivenom at
a final concentration in the 250 µL cuvette volu e of 1% of that of the original vial concentration,
T. mossambicanus clotted the plasma in 9.6 s (SD 0.17 s) instead of the 7.5 s without antivenom,
compared to D. typus, which clotted the plasma at 20.7 s (SD 1.07 s) instea of the 11.2 s without
antiv nom ( able 1). At a 0.05 µg/mL venom concentration, the added antivenom had som effect
on T. mossambicanus, w ich clotted in 381.2 s (SD 4.71 s) instead of 80.4 s without antivenom (Table 1).
D. typus however reached aximum clotting time of 999.9 s (Table 1) at a venom concentration of
0.05 µg/mL with the addition of antivenom, demonstrating a significantly greater effective neutralising
ability against this species.
Comparing EC50 outputs, it is evident that, despite the variation in clotting times between the
species (Figure 8), half-maximal concentration is reached at a similar point by both species. This is due
to the dilution series following the same trajectory regardless of time (Figure 8). When transformed, this
trajectory becomes more evident, as there is little x-axis difference between T. mossambicanus with and
without antivenom (0.24 µg/mL: 95% CI 0.22–0.26 µg/mL, and 0.23 µg/mL: 95% CI 0.20–0.26 µg/mL
respectively) and T. mossambicanus and D. typus without antivenom (0.24 µg/mL and 0.20 µg/mL: 95%
CI 0.18–0.23 µg/mL respectively) (Figure 9). However, when antivenom is introduced with D. typus,
the EC50 x-axis shifts significantly to the right (1.62 µg/mL: 95% CI 1.49–1.76 µg/mL) (Figure 9). Due to
each sub data set being transformed, first by log concentration and then the normalisation of clotting
time, each final data point reaches 100% (Figure 9). Taking into account the y-axis shift in addition
to the x-axis shift (Figure 8), the T. mossambicanus venom has an antivenom induced relative shift in
the clotting curve of 4.69, while the D. typus venom has a antivenom induced relative shift in the
clotting curve o 53.12. Thus the ntive om is 11.3 times more effec ive at neutralizing D. typus venom
than T. mossambicanus venom. Thus if the antivenom had no significant effect upon T. mossambicanus
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under such ideal circumstances as conducted in this study, then there is little chance of it having an
therapeutic effect in a clinical scenario without the use of extreme amounts of antivenom.
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3. Discussion
Both venoms tested here ere found to be highly procoagulant without requiring calcium
or phospholipid as co-factors. However T. mossambicanus is notably more pote t than D. typus,
as well as b ing extremely p orly neutr lised y SAIMR boomslang antivenom (Table 2, Figures 7–9).
The decoupling from co-factors is a notable discovery as this lack of shift betw en tests with or
without c -fa tors had only been well-document d for Echis arinatu . T is is the first extensive
antive m comparison of both species marking the relative effectiveness of the available boomslang
monovalent antiven m.
Previous reports have described these two species as exhibiting strikingly similar lethal
envenomations [17,19–21,30,37–40] that can be attributed to their venoms being dominated by P-III
SVMPs (Figures 2 and 3). It is notable that, despite T. mossambicanus having a lower concentration
of SVMP due to its greater venom complexity, it displayed a higher relative rate of metalloprotease
activity in addition to being more potently coagulotoxic (Figures 4, 7 and 8). Further, T. mossambicanus
possesses two distinct molecular weight classes of SVMP as opposed to the single band present
in D. typus venom (Figure 2). Thus the differential proteomics profile is mirrored by differential
coagulotoxic activity. This key difference between the species’ venom profiles may also shed light as
to why the available antivenom for D. typus has only a small neutralising effect on T. mossambicanus
venom (Figures 8 and 9, Table 1).
Calcium-independent prothrombin activation is a rare feature in snake venoms, with most
venoms typically requiring calcium for such a coagulotoxic activity. A previously documented notable
exception is the ecarin-type P-III SVMP from Echis carinatus, which does not have a marked shift
bet een tests with r without co-factors [25,45]. Thus, the presence of such an activity in the venoms
of these two colubrid snakes points towards a remarkable case of functional convergence within the
same toxin class.
Toxins 2017, 9, 171 12 of 20
Procoagulation accompanied by plasmin inhibition is an effective way to potentiate the
coagulotoxic effects as the blood clots formed would have a longer half-life since the role of plasmin is
to break blood clots down. This synergistic activity has been documented in viper venoms (e.g., Daboia)
and elapid venoms (e.g., Pseudonaja), where the procoagulation is accomplished by very different
toxin types (SVMP and fXa:fVa, respectively), but the plasmin inhibition is exerted by the same toxin
type (kunitz peptide) [46,47]. However, neither D. typus or T. mossambicanus venoms displayed this
synergistic action.
Despite having the same procoagulant mechanism, it appears evident that additional external
evolutionary pressures are driving the variation between these two species. In addition to differential
complexity, the venoms were functionally variable relative to each other in non-procoagulant activities,
with D. typus having serine protease activity (Figure 5), while conversely T. mossambicanus had strong
PLA2 activity (Figure 6). It is known that evolution among arboreal specialists further influences
venom composition of toxins’ families [48]. This is usually in the form of prey ecology, dependent on
niche occupation. Even though both species occupy an arboreal habitat, their differential morphology
and behaviour allow for varying prey interactions, thus potentially further contributing to venom
variation and punctuated evolution. As D. typus is an agile and fast-moving snake, it is able to pursue
prey, thus minimising escape potential. T. mossambicanus however is a slower moving cryptic snake
that ambush feeds, and thus the prey escape potential may be significantly higher. Thus, there may be
a stronger selection pressure operating upon T. mossambicanus for a venom which rapidly immobilises
prey. This is consistent with what has been observed in other lineages of venomous animals in which
prey escape potential is a significant shaping factor and thus the venom is under extreme selection
pressure for rapid immobilising action [2,5,6,15,49–59].
This investigation not only has revealed the differential evolution of D. typus and T. mossambicanus
venoms and the poor performance of boomslang antivenom against T. mossambicanus venom, but it
has also reinforced that there are commonalities to venom evolution such that there may be levels
of predictability in regards to niche occupation and prey escape potential shaping venom relative
rates of action. The differences in ecological niches occupied were also reflected in differential skull
morphology (Figure 1). This reinforces that, in addition to the applied application of venom research
in regards to biodiscovery and clinical effects, research such as this contributes to the growing body of
venom evolutionary theory.
4. Materials and Methods
4.1. Venom Supplies
Pooled venoms from Dispholidus typus (South African origin) and Thelotornis mossambicanus
(Mozambique) were supplied by Latoxan (Portes-lès-Valence, France).
4.2. Micro-Computed Tomography (CT)
We scanned representative boomslang (Dispholidus typus) and the twig snakes (Thelotornis
mossambicanus) with a Siemens Inveon micro-CT scanner. The scanner was operated at 80 KV energy,
250 µA intensity with 360 projections per 360◦, and 2300 ms exposure time. The samples were scanned
at a nominal isotropic resolution of 27.8 um. The data were reconstructed using a Feldkamp conebeam
back-projection algorithm provided by an Inveon Acquisition Workstation from Siemens. The images
in 3D were visualized and processed with ImageJ v1.51f [60], Materialise Mimics v19.0 (Materialise,
Leuven, Belgium), and MeshLab v1.3.3 (Institute of the National Research Council of Italy, Pisa, Italy).
4.3. Magnetic Resonance Imaging
MRI was used to obtain a three-dimensional (3D) shape of the venom glands without intrusive
dissection or sectioning techniques. For fixation, neutral buffered formalin (NBF) preserved specimens
had the formalin removed by four individual hours of washing steps in phosphate buffered saline (PBS)
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and incubated overnight in 0.1% Magnevist® (Bayer, Leverkusen, Germany) in PBS. After the removal
of NBF, the sample was submersed in perfluoro-ether Fomblin (Solvay Solexis, Alessandria, Italy) and
placed under vacuum to prevent air artifacts. Imaging was performed on a 16.4 T (700 MHz) vertical
89-mm-bore system (Bruker BioSpin, Rheinstetten, Germany) using a Bruker Micro 2.5 gradient system
(2.5 G/cm A), transmit/receive radiofrequency coils with diameters of 10 mm, and a quadrature
birdcage resonator (M2M Imaging, Brisbane, Australia). Bruker ParaVision 6.0.1 software was
used for image acquisition and anatomical images were acquired using a 3D FLASH (Fast Low
Angle Shot) gradient echo sequence. The imaging parameters were: TR/TE = 50/8 ms, flip angle
30 ◦C, two excitations. The field-of-view and matrix sized to fit the sample with the resulting voxels
having 50–62.5 µm isotropic resolution. Total scan time was approximately 1 h per sample. MRI
data was processed using Medical Imaging Processing, Analysis, and Visualization v6.0.0 (MIPAV,
Centre for Information Technology, National Institutes of Health, Bethesda, MD, USA), and 3D
image segmentation, surface rendering, and volumetric measurements of the glands were performed
manually using ITK-SNAP [61].
4.4. Proteomics
Our proteomic investigations including using 1D and 2D SDS-PAGE, protein band purification
and crude venom Shotgun analysis. They were performed as previously described by us [48] with
the exception of additional LC-MS/MS analysis, following protein extraction from isolated 1D gel
bands (described below in Sections 4.4.1 and 4.4.2). Shotgun samples were analyzed using the methods
described below (Section 4.4.3).
4.4.1. Nano HPLC-ESI-Triple Time of Flight (TOF) Mass Spectral Analysis
Protein extracts from gel bands were analysed by LC-MS/MS using a Q Exactive™ Hybrid
Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped
with a nano electrospray ion source. An aliquot (8 µL) of each extract was injected onto a C18 trap
column (75 µm × 2 cm, Thermo Scientific, Waltham, MA, USA) at 6 µL/min. Samples were de-salted
on the trap column for 5 min using 0.1% formic acid at 6 µL/min. The trap column was then placed
in-line with the analytical nano HPLC column (15 cm × 75 µm C18, 3.5 µm, Thermo Fisher Scientific,
Waltham, MA, USA) for mass spectrometry analysis. Solvent A consisted of 2% ACN/0.1% formic
acid, and solvent B contained 100% ACN, 2% LC-MS water, and 0.1% formic acid. Peptide elution
was made possible via linear gradients of 1 to 40% solvent B over 32 min at 300 nL/min flow rate,
followed by a steeper gradient from 40 to 95% solvent B over 3 min. Solvent B was held at 95% for
2.5 min to allow for washing of the column and returned to 1% solvent B for equilibration prior to the
next sample injection. The ion spray voltage was set to 1.8 kV, and the temperature of capillary was
300 ◦C. The mass spectrometer acquired 3 × 106 ion count with the max injection time of 20 ms for
a full scan TOF-MS data followed by 106 ions count with the max injection time of 110 ms for a full
scan product ion data in an Information Dependant Acquisition (IDA) mode. Full scan TOF-MS data
was acquired over the mass range of 300–1800 m/z, while the product ion ms/ms was 100–1800 m/z.
Ions observed in the TOF-MS scan exceeding a threshold of 1.8 × 105 for the precursor selection with
a charge state of +1 to +8 were set to trigger the acquisition of the product ion, with ms/ms spectra of
the resultant 20 most intense ions. The data was acquired and processed using Xcalibur™ software
(Thermo Fisher Scientific, Waltham, MA, USA).
4.4.2. Protein Identification
Protein database searches were conducted against Uniprot for broad protein identification.
A composite target decoy database was built with the forward and reverse sequences for calculating the
FDR. Proteins were identified by database searching using PEAKS v7.5 (Bioinformatics Solutions Inc.,
Waterloo, ON, Canada) against the protein database. The search parameters were as follows: precursor
ion mass tolerance, 10 ppm; fragment ion mass tolerance, 0.05 Da; fully tryptic enzyme specificity; one
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missed cleavage; monoisotopic precursor mass a fixed modification of cysteine carbamidomethylation;
and variable modifications, including methionine oxidation, conversion of glutamine and glutamic
acid to pyroglutamic acid, deamidation of asparagine, phosphorylation, acetylation, and sulfation.
For PEAKS, de novo sequencing, database search, and characterising unspecific post-translational
modifications (PTMs) were used to maximise the identifications; false discovery rate (FDR) was set to
≤1%; and the individual peptide ion score [−10·Log(p)] was calculated accordingly, where p is the
probability that the observed match is a random event.
4.4.3. Orbitap Elite Mass Spectrometer for SHOTGUNS
For LC-MS/MS analysis, the parameters are as follows; the samples were separated using
RP-chromatography on a Dionex Ultimate 3000 RSLC nano-system (Lifetech, Carlsbad, CA, USA). The
samples were desalted on a Thermo PepMap 100 C18 trap (Lifetech, Carlsbad, CA, USA) (0.3 × 5 mm,
5 µm) for 5 min with a flow rate of 30 µL/min. This was followed by separation on an Acclaim PepMap
RSLC C18 (Lifetech, Carlsbad, CA, USA) (150 mm × 75 µm) column at a flow rate of 300 nL/min.
A gradient of 10–70% was applied buffer B over 7 min, where buffer A (1% ACN/0.1% FA) and
buffer B (80% ACN/0.1% FA) were used to separate peptides. The eluted peptides were directly
analysed on an Orbitap Elite mass spectrometer (Thermo Scientific, Carlsbad, CA, USA) using an
NSI electrospray interface. The source parameters included a capillary temperature of 275 ◦C; S-Lens
RF level at 60%, source voltage of 2 kV, and maximum injection times of 200 ms for MS and 150 ms
for MS2. The instrument parameters included an FTMS scan across m/z range 350–1800 at 60,000
resolution followed by information dependent acquisition of the top 10 peptides across m/z 40–1800.
Dynamic ion exclusion was employed using a 15 s interval. Charge state screening was enabled
with the rejection of +1 charged ions, and monoisotopic was precursor selection enabled. Data was
converted to mascot generic format (mgf) using the msConvert software (ProteoWizard v3.0.9576,
SCIEX, Concord, ON, Canada) and searched using Protein Pilot™ v5.0 (SCIEX, Concord, ON, Canada)
via the Uniprot database “metazoan”.
4.5. Enzymatic Activity Assays
4.5.1. Fluorescent Determination of Matrix Metalloprotease and Kallikrein Activity
A working stock solution of freeze dried venom was reconstituted in a buffer containing 50%
MilliQ/50% glycerol (>99.9%, Sigma, St. Louis, MO, USA) at a 1:1 ratio to preserve enzymatic
activity and reduce enzyme degradation. Varying concentrations of crude venom (10 ng/µL and
50 ng/µL) were plated out in triplicates on a 384-well plate (black, Lot#1171125, nunc™ Thermo
Scientific, Rochester, NY, USA) and measured by adding 90 µL quenched fluorescent substrate per
well (total volume 100 µL/well, 10 µL/5mL enzyme buffer, 150 mM NaCl, and 50 mM Tri-HCl
(pH 7.3), Fluorogenic Peptide Substrate, R&D systems, Cat#ES001 & ES011, Minneapolis, MI, USA).
Fluorescence was monitored by a Fluoroskan Ascent™ (Thermo Scientific, Vantaa, Finland) Microplate
Fluorometer (Cat#1506450, Thermo Scientific, Vantaa, Finland) (Cat#ES001 for Matrix Metalloprotease
at an excitation of 320 nm, emission at 405 nm; Cat#ES011 for Kallikrein at an excitation of 390 nm,
emission at 460 nm) over 400 mins or until activity had ceased. Data was collected using Ascent®
Software v2.6 (Thermo Scientific, Vantaa, Finland).
4.5.2. Fluorescent Determination of PLA2 Activity
We assessed the continuous Phospholipase A2 (PLA2) activity of the venoms using a fluorescence
substrate assay (EnzChek® Phospholipase A2 Assay Kit, Cat#E10217, Thermo Scientific, Rochester, NY,
USA), measured on a Fluoroskan Ascent® Microplate Fluorometer (Cat#1506450, Thermo Scientific,
Vantaa, Finland). As above, we used a working stock solution of freeze dried venom reconstituted in
a buffer containing 50% MilliQ/50% glycerol (>99.9%, Sigma) at a 1:1 ratio. A concentration of enzyme
activity in venom (50 ng/µL) was brought up in 12.5 µL 1× PLA2 reaction buffer (50 mM Tris-HCL,
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100 mM NaCl, 1 mM CaCl2, pH 8.9) and plated out in triplicates on a 384-well plate (black, Lot#1171125,
nunc™ Thermo Scientific, Rochester, NY, USA). The triplicates were measured by dispensing 12.5 µL
quenched 1 mM EnzChek® (Thermo Scientific, Rochester, NY, USA) Phospholipase A2 Substrate per
well (total volume 25 µL/well) over 100 min or until activity had ceased (at an excitation of 485 nm,
emission 538 nm). Purified PLA2 from bee venom (1 U/mL) was used as a positive control and data
was collected using Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland).
4.5.3. Enzymatic Statistical Analysis
For each of the methods performed on the Fluoroskan Ascent™ (Thermo Scientific, Vantaa,
Finland) Microplate Fluorometer (Cat#1506450, Thermo Scientific, Vantaa, Finland), data was collected
using Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). All raw data were firstly blank
corrected using the Ascent® software (v2.6, Thermo Scientific, Vantaa, Finland) package and then
exported for further analysis using Windows Excel 2016 and GraphPad PRISM 7.0 (GraphPad Prism
Inc., La Jolla, CA, USA).
Graphs: Using Excel, averages of blank corrected data triplicates were calculated. From these
averages, maximum absorbance was calculated and absorbance value plotted in a column graph for
relative percentages.
Two-way (RM) ANOVA and Tukey’s Post-hoc test: the blank corrected data was transformed,
setting the top value as 100 and lowest as 0 across sub columns within a data set. A two-way repeated
measures (RM) ANOVA was performed, followed by a Tukey’s post-hoc multiple comparison test,
comparing every mean with every other mean.
4.6. Procoagulation Analysis
4.6.1. Whole Plasma Clotting
Healthy human plasma (citrate 3.2%, Lot#1690252, approval # 16-04QLD-10) was obtained from
the Australian Red Cross (44 Musk Street, Kelvin Grove, Queensland 4059). Coagulopathic toxin effects
were measured by a modified procoagulant protocol on a Stago STA-R Max coagulation robot (France)
using Stago Analyser software v0.00.04 (Stago, Asniéres sur Seine, France). Plasma clotting baseline
parameters were determined by performing the standardised activated Partial Thromboplastin Time
(aPTT) test (Stago Cat# T1203 TriniCLOT APTT HS). This was used as a control to determine the
health of normal clotting plasma according to the universal standard range of between 27–35 s. Plasma
aliquots of 2 mL, which had been flash frozen in liquid nitrogen and stored in a −80 ◦C freezer, were
defrosted in an Arctic refrigerated circulator SC150-A40 at 37 ◦C. In order to determine clotting times
effected by the addition of varying venom concentrations, a modified aPTT test was developed.
A starting volume of 50 µL of crude venom (5 µg/50 µL) was diluted with STA Owren Koller
Buffer (Stago Cat# 00360). A 14-dilution series of 1 (20 µg/mL), 1/2 (10 µg/mL), 1/3 (6.66 µg/mL),
1/4 (5 µg/mL), 1/6 (3.33 µg/mL), 1/8 (2.5 µg/mL), 1/10 (2 µg/mL), 1/15 (1.33 µg/mL), 1/20
(1 µg/mL), 1/30 (0.66 µg/mL), 1/50 (0.4 µg/mL), 1/80 (0.25 µg/mL), 1/160 (0.125 µg/mL), and 1/400
(0.05 µg/mL) was performed in triplicate. CaCl2 (50 µL; 25 mM stock solution Stago Cat# 00367 STA
CaCl2 0.025M) was added with 50 µL phospholipid (solubilized in Owren Koller Buffer adapted from
STA C.K Prest standard kit, Stago Cat# 00597). An additional 25 µL of Owren Koller Buffer was added
to the cuvette and incubated for 30 s at 37 ◦C before adding 75 µL of human plasma. Relative clotting
was then monitored for 999 s or until plasma clotted (whichever was sooner). Additional tests were
run, both with and without CaCl2 and phospholipid, respectively, to test for CaCl2 or phospholipid
dependency. STA Owren Koller Buffer was used as a substitute, using the same volumes to allow for
consistency in the final volumes (250 µL).
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4.6.2. Antivenom Studies
The monovalent antivenom effects on both D. typus and T. mossambicanus crude venoms was
investigated. Previously established whole plasma clotting times against both venoms were measured
and used as a guide for antivenom effects. The South African Institute for Medical Research Boomslang
Antivenom (refined equine immunoglobulins, Lot M03852) was purchased from South African Vaccine
Producers Pty Ltd (1 Modderfontein Rd Edenvale, Gauteng, South Africa). One vial of antivenom
(10 mL) was centrifuged at 12,000 rpm on an Allegra™ X-22R Centrifuge (Lot#982501, Beckman
Coulter, Brea, CA, USA) for 10 min at 4 ◦C, supernatant extracted, filtered (0.45 µm Econofltr PES,
Lot#131127028, Agilent Technologies, Beijing, China) and stored at 4 ◦C. A final stock solution of 10%
antivenom and 90% Owren Koller Buffer was produced. Modifying the Section 4.4.1 protocol, 25 µL
of antivenom stock was used in place of 25 µL of OK buffer, with the venom, Ca2+, phospholipid,
and antivenom mixture being incubated for 120 s at 37 ◦C before adding 75 µL of human plasma
and monitoring clotting for 999 s or until plasma clotted (whichever was sooner). Experiments were
conducted in triplicate. Note that antivenom does not clot plasma and that a control was performed
to rule out any additional effects antivenom has on the plasma. Antivenom was substituted into the
above outlined protocol in replacement of a venom sample.
4.6.3. Statistical Analysis
Whole Plasma Clotting EC50 Concentration and Asymptotic Time
Venom dilutions in triplicates were mapped over time using GraphPad PRISM 7.0 to produce
concentration curves. The statistical program R [62] was used to calculate asymptotic clotting times
using the Asymptotic Regression Model. This can be written as y(x) = ϕ1 + (ϕ2 − ϕ1) exp[−exp(ϕ3)x],
using the nlme package [63]. This asymptotic regression model was used to model the response of y
(time) when approaching a horizontal asymptote, when x (concentration) approaches ∞ [64]. In this
example, ϕ1 is the asymptote as x (concentration) approaches ∞, ϕ2 is the response at x = 0, and t0.5 is
the half-life. Parameter ϕ3 is the logarithm of the rate constant that is used to enforce positivity so that
an asymptote is reached in the model. The corresponding half-life is written as t0.5 = log2/exp(ϕ3).
The EC50 can be explained as the half-maximal Effective Concentration, or the concentration at which
50% of the maximal effect is observed. To calculate this, the EC50 function in GraphPad PRISM 7.0 was
used for each data set. Each data set was transformed by the log of the concentration, and the values
were normalised by individual sub data sets. A non-linear regression curve fit was then modelled, and
a log-reversed EC50 value was produced.
Antivenom EC50 Concentration
Venom dilutions in triplicates were mapped over time using GraphPad PRISM 7.0 to produce
concentration curves. The EC50 function in GraphPad PRISM 7.0 was used to calculate the EC50 for
each data set. Each data set was transformed by the log of the concentration, and the values were
normalised by individual sub data sets. A non-linear regression curve fit was then modelled, and a
log-reversed EC50 value was produced.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/5/171/s1,
Supplementary data: MS/MS data.
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The following abbreviations are used in this manuscript:
CI confidence interval
aPTT activated partial thromboplastin time
SVMP snake venom metalloprotease
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
CRiSP cysteine rich secretory protein
HPLC high pressure liquid chromatography
SD standard deviations
ACN acetonitrile
1D one dimensional
2D two dimensional
3FTx three finger toxin
PLA2 phospholipase A2
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